193 related articles for article (PubMed ID: 12437373)
41. Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.
Yarbrough WG; Buckmire RA; Bessho M; Liu ET
J Natl Cancer Inst; 1999 Sep; 91(18):1569-74. PubMed ID: 10491434
[TBL] [Abstract][Full Text] [Related]
42. HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p16Ink4a and counteracts its inhibitory activity to CDK4.
Suzuki T; Yoshida M
Leukemia; 1997 Apr; 11 Suppl 3():14-6. PubMed ID: 9209282
[TBL] [Abstract][Full Text] [Related]
43. Structural characterization of the tumor suppressor p16, an ankyrin-like repeat protein.
Boice JA; Fairman R
Protein Sci; 1996 Sep; 5(9):1776-84. PubMed ID: 8880901
[TBL] [Abstract][Full Text] [Related]
44. An NF-kappaB-specific inhibitor, IkappaBalpha, binds to and inhibits cyclin-dependent kinase 4.
Li J; Joo SH; Tsai MD
Biochemistry; 2003 Nov; 42(46):13476-83. PubMed ID: 14621993
[TBL] [Abstract][Full Text] [Related]
45. Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations.
Cammett TJ; Luo L; Peng ZY
J Mol Biol; 2003 Mar; 327(1):285-97. PubMed ID: 12614625
[TBL] [Abstract][Full Text] [Related]
46. Tumor suppressor INK4: quantitative structure-function analyses of p18INK4C as an inhibitor of cyclin-dependent kinase 4.
Li J; Poi MJ; Qin D; Selby TL; Byeon IJ; Tsai MD
Biochemistry; 2000 Feb; 39(4):649-57. PubMed ID: 10651629
[TBL] [Abstract][Full Text] [Related]
47. Identification of CDK4 sequences involved in cyclin D1 and p16 binding.
Coleman KG; Wautlet BS; Morrissey D; Mulheron J; Sedman SA; Brinkley P; Price S; Webster KR
J Biol Chem; 1997 Jul; 272(30):18869-74. PubMed ID: 9228064
[TBL] [Abstract][Full Text] [Related]
48. Alterations of pRb1-cyclin D1-cdk4/6-p16(INK4A) pathway in endometrial carcinogenesis.
Semczuk A; Jakowicki JA
Cancer Lett; 2004 Jan; 203(1):1-12. PubMed ID: 14670612
[TBL] [Abstract][Full Text] [Related]
49. Phosphorylation of p16INK4A correlates with Cdk4 association.
Gump J; Stokoe D; McCormick F
J Biol Chem; 2003 Feb; 278(9):6619-22. PubMed ID: 12529334
[TBL] [Abstract][Full Text] [Related]
50. S-phase lengthening induced by p16(INK4a) overexpression in malignant cells with wild-type pRb and p53.
Chien WW; Domenech C; Catallo R; Salles G; Ffrench M
Cell Cycle; 2010 Aug; 9(16):3286-96. PubMed ID: 20703084
[TBL] [Abstract][Full Text] [Related]
51. Frequent deregulation of p16 and the p16/G1 cell cycle-regulatory pathway in neuroblastoma.
Diccianni MB; Omura-Minamisawa M; Batova A; Le T; Bridgeman L; Yu AL
Int J Cancer; 1999 Jan; 80(1):145-54. PubMed ID: 9935245
[TBL] [Abstract][Full Text] [Related]
52. CDK4, CDK6, cyclin D1, p16(INK4a) and EGFR expression in glioblastoma with a primitive neuronal component.
Xu G; Li JY
J Neurooncol; 2018 Feb; 136(3):445-452. PubMed ID: 29150788
[TBL] [Abstract][Full Text] [Related]
53. Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein.
Ikuta M; Kamata K; Fukasawa K; Honma T; Machida T; Hirai H; Suzuki-Takahashi I; Hayama T; Nishimura S
J Biol Chem; 2001 Jul; 276(29):27548-54. PubMed ID: 11335721
[TBL] [Abstract][Full Text] [Related]
54. Tumor suppressor gene p16/INK4A/CDKN2A-dependent regulation into and out of the cell cycle in a spontaneous canine model of breast cancer.
Agarwal P; Sandey M; DeInnocentes P; Bird RC
J Cell Biochem; 2013 Jun; 114(6):1355-63. PubMed ID: 23238983
[TBL] [Abstract][Full Text] [Related]
55. Regulation of CDK4 activity by a novel CDK4-binding protein, p34(SEI-1).
Sugimoto M; Nakamura T; Ohtani N; Hampson L; Hampson IN; Shimamoto A; Furuichi Y; Okumura K; Niwa S; Taya Y; Hara E
Genes Dev; 1999 Nov; 13(22):3027-33. PubMed ID: 10580009
[TBL] [Abstract][Full Text] [Related]
56. Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines.
McLaughlin-Drubin ME; Park D; Munger K
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16175-80. PubMed ID: 24046371
[TBL] [Abstract][Full Text] [Related]
57. Expression and characterization of Syrian golden hamster p16, a homologue of human tumor suppressor p16 INK4A.
Li J; Qin D; Knobloch TJ; Tsai MD; Weghorst CM; Melvin WS; Muscarella P
Biochem Biophys Res Commun; 2003 May; 304(2):241-7. PubMed ID: 12711305
[TBL] [Abstract][Full Text] [Related]
58. CDK redundancy guarantees cell cycle progression in Rb-negative tumor cells independently of their p16 status.
Santamariña M; Hernández G; Zalvide J
Cell Cycle; 2008 Jul; 7(13):1962-72. PubMed ID: 18604173
[TBL] [Abstract][Full Text] [Related]
59. A novel function for the tumor suppressor p16(INK4a): induction of anoikis via upregulation of the alpha(5)beta(1) fibronectin receptor.
Plath T; Detjen K; Welzel M; von Marschall Z; Murphy D; Schirner M; Wiedenmann B; Rosewicz S
J Cell Biol; 2000 Sep; 150(6):1467-78. PubMed ID: 10995450
[TBL] [Abstract][Full Text] [Related]
60. Crystal structure of the homolog of the oncoprotein gankyrin, an interactor of Rb and CDK4/6.
Padmanabhan B; Adachi N; Kataoka K; Horikoshi M
J Biol Chem; 2004 Jan; 279(2):1546-52. PubMed ID: 14583612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
